554 related articles for article (PubMed ID: 33220249)
21. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
Yki-Järvinen H
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
[TBL] [Abstract][Full Text] [Related]
22. Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents.
Cardoso AS; Gonzaga NC; Medeiros CC; Carvalho DF
J Pediatr (Rio J); 2013; 89(4):412-8. PubMed ID: 23791233
[TBL] [Abstract][Full Text] [Related]
23. [New trends in non-alcoholic fatty liver diseases (NAFLD)].
Barigou M; Favre L; Fraga M; Artru F
Rev Med Suisse; 2020 Mar; 16(687):586-591. PubMed ID: 32216182
[TBL] [Abstract][Full Text] [Related]
24. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B.
Han E; Lee YH; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH; Kim SU
Aliment Pharmacol Ther; 2018 Aug; 48(3):300-312. PubMed ID: 29920701
[TBL] [Abstract][Full Text] [Related]
25. [Non-alcoholic fatty liver disease - a summary and update based on the EASL-EASD-EASO Clinical Practice Guidelines of 2016].
Nádasdi Á; Somogyi A; Igaz P; Firneisz G
Orv Hetil; 2018 Nov; 159(45):1815-1830. PubMed ID: 30415572
[TBL] [Abstract][Full Text] [Related]
26. Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease.
Polyzos SA
Minerva Endocrinol; 2017 Jun; 42(2):89-91. PubMed ID: 27792216
[No Abstract] [Full Text] [Related]
27. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease.
Patel SS; Siddiqui MS
Drugs; 2019 Jan; 79(1):75-84. PubMed ID: 30588564
[TBL] [Abstract][Full Text] [Related]
28. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation.
Carter D; Dieterich DT; Chang C
Clin Liver Dis; 2018 Feb; 22(1):213-227. PubMed ID: 29128058
[TBL] [Abstract][Full Text] [Related]
29. The relationship between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non-alcoholic fatty liver disease.
Chiyanika C; Chan DFY; Hui SCN; So HK; Deng M; Yeung DKW; Nelson EAS; Chu WCW
Pediatr Obes; 2020 Sep; 15(9):e12653. PubMed ID: 32351030
[TBL] [Abstract][Full Text] [Related]
30. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease.
Souza MR; Diniz Mde F; Medeiros-Filho JE; Araújo MS
Arq Gastroenterol; 2012; 49(1):89-96. PubMed ID: 22481692
[TBL] [Abstract][Full Text] [Related]
31. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
Hussain A; Vasas P; El-Hasani S
Metabolism; 2020 Jul; 108():154256. PubMed ID: 32360211
[No Abstract] [Full Text] [Related]
32. Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
Dietrich CG; Geier A; Merle U
World J Gastroenterol; 2023 Jan; 29(2):367-377. PubMed ID: 36687116
[TBL] [Abstract][Full Text] [Related]
33. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.
Eslam M; Ahmed A; Després JP; Jha V; Halford JCG; Wei Chieh JT; Harris DCH; Nangaku M; Colagiuri S; Targher G; Joshi S; Byrne CD; Khunti K; Nguyen MH; Gish RG; George J
Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):743-753. PubMed ID: 34265276
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 Coagulopathy with Superior Mesenteric Vein Thrombosis Complicated by an Ischaemic Bowel.
Fan BE; Chang CCR; Teo CHY; Yap ES
Hamostaseologie; 2020 Dec; 40(5):592-593. PubMed ID: 32894875
[TBL] [Abstract][Full Text] [Related]
35. Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease.
Jung HN; Jung CH
Diabetes Metab J; 2023 Mar; 47(2):198-200. PubMed ID: 36944452
[No Abstract] [Full Text] [Related]
36. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease.
Bhat G; Baba CS; Pandey A; Kumari N; Choudhuri G
Trop Gastroenterol; 2013; 34(1):18-24. PubMed ID: 23923370
[TBL] [Abstract][Full Text] [Related]
37. Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health.
Chitturi S; Farrell GC
J Gastroenterol Hepatol; 2007 Jul; 22(7):967-9. PubMed ID: 17608841
[No Abstract] [Full Text] [Related]
38. Indian College of Physicians Position Statement on Anemia in Metabolic Syndrome.
Sahay M; Kalra S; Tiwaskar M; Ghosh S; Badani R; Bantwal G; Das AK; Dhorepatil B; Jeloka T; Khandelwal D; Nadkar MY; Saboo B; Sahay R; Unnikrishnan AG; Aggarwal S; Agrawal N; Bajaj S; Baruah MP; Chadha M; Das S; Dhamija P; Julka S; Mehta P; Shah SN; Sharma B; Muruganathan A
J Assoc Physicians India; 2017 Jun; 65(6):60-73. PubMed ID: 28782315
[No Abstract] [Full Text] [Related]
39. Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy.
Maevskaya MV; Ivashkin VT; Ivashkin KV; Lunkov VD; Liusina EO; Zozula VN; Leshchenko VI
Ter Arkh; 2019 Mar; 91(2):109-117. PubMed ID: 31094181
[TBL] [Abstract][Full Text] [Related]
40. [The Development of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease].
Kwon OS; Kim JH; Kim JH
Korean J Gastroenterol; 2017 Jun; 69(6):348-352. PubMed ID: 28637103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
